Diatech Pharmacogenetics is the unique company in Italy focusing its research efforts on pharmagonenetics, the science that studies the genetic variation that effects response to drugs, as well as underpins understanding on what side effects are likely to occur (personalised medicine).

Diatech Pharmacogenetics supports its own research efforts commercializing and developing pharmacogenetic tests implemented in the personalised and predictive medicine, with priority focused on the most invasive therapies: anti-cancer treatments. Pharmacogenetic kits developed by Diatech Pharmacogenetics target to personalize chemotherapy and radiotherapy cancer treatments, leading to higher efficacy and reduced side effects.

Empire Genomics was created in 2006 from research started at the prestigious Roswell Park Cancer Institute in Buffalo, New York. The laboratory has a strong track record in the development of high throughput technologies to enable genome-wide analyses aimed at determining the underlying mechanisms for diseases.

Empire Genomics is committed to working with the scientific community to bring the best in genomic technologies to bear on the complex systems biology questions that we collectively seek to answer and to remove costly variation, inconsistency and the lack of reproducibility that has prevented the field from rapidly moving forward with discoveries.

InterpretOmics is a life Sciences technology company that provides an On-Premise and SaaS enterprise-grade unified software platform and database for pharmaceuticals, biotechnology, hospitals, and agricultural firms to analyze genetic information and identify biomarkers critical to the development of targeted drugs, therapies, and crops

Their data scientists help the client scientists customize the platform and subsequently use the software infrastructure for translating hypothesis into discovery.

Lexogen is a biotech company with unique proprietary expression profiling technologies that enable detailed analysis of the complete transcriptome as well as individual full length RNAs of interest.

Lexogen was founded in 2007 with the support of both private capital and public funds. Lexogen is supported by the Austrian Research Promotion Agency FFG, the Austria Wirtschaftsservice AWS, INiTS and the Wirtschaftsagentur Wien.

Lexogen is based in Vienna, Austria, and has a subsidiary in New Hampshire, USA. 50% of Lexogen employees work in R&D.

Rubicon Genomics is a privately held company located in Ann Arbor, Michigan. It was founded in 2000 by two University of Michigan faculty members, Dr. John Langmore and Dr. Vladimir Makarov, who wanted to advance the translation of human genetics “laboratory knowledge” into practical medical applications.

The products combined with strategic partnerships have established the company as a leader in pre-analytical amplification technologies. Company’s core competencies, including enzymology, nucleic acid chemistry, sample processing and manufacturing, have served as engines for innovation, development of intellectual property, and ongoing product development.

ScreenCell was founded with the objective of designing and producing a simple but revolutionary technology allowing the fast and effective isolating of Rare Circulating Cells yielding free of any bias CTC population amenable to better cellular and molecular characterization important in cancer monitoring. This technology also contributes to the development of a new non-invasive approach to prenatal diagnosis.

Screencell is dedicated to creating technologies allowing CTCs to become potential end points in future oncology therapeutic arsenals, by filtering out healthy live tumor cells.

transOMIC technologies Inc. is a newly founded biotechnology based out of Huntsville, USA. It is focused on providing the life science research market with innovative technologies and research tools to accelerate the quest towards elucidating the complexity of life and human disease.

transOmic’s product portfolio is developed through close collaborations with the world’s leading research institutes enabling rapid commercialization of next generation tools and technologies to make them broadly accessible to the research community.